Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT05942066
Recruiting Observational

Feasibility Study Aiming at Pre-Analytical Standardization of Whole Blood Processing for Liquid Biopsy Applications

NCT05942066 · tracked via the Priya Life Science Italy tracker
Sponsor
Tethis S.p.A
Phase
Observational
Started
2023-10-09
Last updated
2026-02-12

Condition(s) studied

Healthy Participants

Study summary

The goal of this feasibility study is to evaluate a new sample preparator called See.d.

After blood processing the instrument will produce a set of slides and a tube of plasma. These outputs could be used in further analysis in liquid biopsy applications.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Participants are willing and able to give and sign a written informed consent * Aged 18 or above Exclusion Criteria: * Ongoing infections requiring antibiotic or antiviral treatment * Known hemostasis/coagulation disorder * Known Pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Ospedale San Raffaele Milan Italy Recruiting

More Tethis S.p.A. trials in Italy

Identification of Prostate Cancer Specific Markers in Patients Compared to Healthy Participants Active, not recruiting
Identification of Breast Cancer Specific Markers in Patients Compared to Healthy Participants Active, not recruiting
Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications Recruiting

Other trials for the same condition

Bariatric Surgery and Gut Microbiota Changes Over Time Starting soon
Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05942066 on ClinicalTrials.gov ↗ ← All trials in Italy